Ariel Dora Stern
Ariel Dora Stern
Associate Professor, Harvard Business School
Vahvistettu sähköpostiosoite verkkotunnuksessa - Kotisivu
Physician beliefs and patient preferences: a new look at regional variation in health care spending
D Cutler, JS Skinner, AD Stern, D Wennberg
American Economic Journal: Economic Policy 11 (1), 192-221, 2019
Will the stork return to Europe and Japan? Understanding fertility within developed nations
J Feyrer, B Sacerdote, AD Stern
Journal of Economic Perspectives 22 (3), 3-22, 2008
Did the rust belt become shiny? A study of cities and counties that lost steel and auto jobs in the 1980s [with Comments]
J Feyrer, B Sacerdote, AD Stern, A Saiz, WC Strange
Brookings-Wharton Papers on Urban Affairs, 41-102, 2007
Evaluating the impact of the Baby-Friendly Hospital Initiative on breast-feeding rates: a multi-state analysis
SS Hawkins, AD Stern, CF Baum, MW Gillman
Public health nutrition 18 (2), 189-197, 2015
Adaptive platform trials: definition, design, conduct and reporting considerations.
DC Angus, BM Alexander, S Berry, M Buxton, R Lewis, M Paoloni, ...
Nature Reviews Drug Discovery 18 (10), 797-808, 2019
Innovation under regulatory uncertainty: Evidence from medical technology
AD Stern
Journal of public economics 145, 181-200, 2017
Compliance with the Baby-Friendly Hospital Initiative and impact on breastfeeding rates
SS Hawkins, AD Stern, CF Baum, MW Gillman
Archives of Disease in Childhood-Fetal and Neonatal Edition 99 (2), F138-F143, 2014
Do state breastfeeding laws in the USA promote breast feeding?
SS Hawkins, AD Stern, MW Gillman
J Epidemiol Community Health 67 (3), 250-256, 2013
Limits on use of health economic assessments for rare diseases
HI Hyry, AD Stern, TM Cox, JCP Roos
QJM: An International Journal of Medicine 107 (3), 241-245, 2014
The impact of the entry of biosimilars: evidence from Europe
FMS Morton, AD Stern, S Stern
Review of Industrial Organization 53 (1), 173-210, 2018
How economics can shape precision medicines
AD Stern, BM Alexander, A Chandra
Science 355 (6330), 1131-1133, 2017
Innovation incentives and biomarkers
AD Stern, BM Alexander, A Chandra
Clinical Pharmacology & Therapeutics 103 (1), 34-36, 2018
Characterizing the drug development pipeline for precision medicines
A Chandra, C Garthwaite, AD Stern
National Bureau of Economic Research, 2017
Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries
S Gerke, AD Stern, T Minssen
NPJ digital medicine 3 (1), 1-6, 2020
Quantifying the use of connected digital products in clinical research
C Marra, JL Chen, A Coravos, AD Stern
NPJ digital medicine 3 (1), 1-5, 2020
The impact of price regulation on the availability of new drugs in Germany
AD Stern, F Pietrulla, A Herr, AS Kesselheim, A Sarpatwari
Health Affairs 38 (7), 1182-1187, 2019
It’s time to reform the Orphan Drug Act
N Bagley, A Chandra, C Garthwaite, AD Stern
NEJM Catalyst 4 (6), 2018
Economic implications of the Society for Assisted Reproductive Technology embryo transfer guidelines: healthcare dollars saved by reducing iatrogenic triplets
MS Lee, BT Evans, AD Stern, MD Hornstein
Fertility and sterility 106 (1), 189-195. e3, 2016
Cybersecurity features of digital medical devices: an analysis of FDA product summaries
AD Stern, WJ Gordon, AB Landman, DB Kramer
BMJ open 9 (6), e025374, 2019
Challenges and opportunities in software-driven medical devices
WJ Gordon, AD Stern
Nature biomedical engineering 3 (7), 493-497, 2019
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20